Ionis Pharmaceuticals, Inc. $IONS
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS17
PHASE 3 / 2-312
RECRUITING6
READOUTS ≤12 MONTHS7
READOUT SLIPPED >6 MO83%
Delay Index: of 12 active trials registered more than a year ago, 10 have moved their primary completion (readout) date by more than 6 months since first registration (median +26.0 months). See all sponsors →
Open Ionis Pharmaceuticals, Inc. on the live radar map → 📅 $IONS readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| zilganersen NCT04849741 |
P3 | Active, not recruiting | Alexander Disease | 54 | 2025-08-22 (+19 mo) |
| ION363 NCT04768972 |
P3 | Active, not recruiting | Amyotrophic Lateral Sclerosis | 89 | 2026-06-17 (+28 mo) |
| Donidalorsen NCT05392114 |
P3 | Active, not recruiting | Hereditary Angioedema | 154 | 2026-12 (+26 mo) |
| Olezarsen NCT05681351 |
P3 | Active, not recruiting | Severe Hypertriglyceridemia | 885 | 2027-03 (+10 mo) |
| ION717 NCT06153966 |
P1/2 | Active, not recruiting | Prion Disease | 85 | 2027-04 (+25 mo) |
| Olezarsen NCT05185843 |
P3 | Active, not recruiting | Familial Chylomicronemia Syndrome | 24 | 2027-06 (+30 mo) |
| obudanersen NCT06914609 |
P3 | Active, not recruiting | Angelman Syndrome | 156 | 2027-08 |
| ION440 NCT06430385 |
P1/2 | Recruiting | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | 48 | 2027-09 (+16 mo) |
| ION775 NCT07604974 |
P2 | Recruiting | Hypertriglyceridemia; Severe Hypertriglyceridemia | 72 | 2027-09 |
| Olezarsen NCT05130450 |
P3 | Active, not recruiting | Familial Chylomicronemia Syndrome | 60 | 2028-02 (+38 mo) |
| obudanersen NCT07782827 |
P3 | Recruiting | Angelman Syndrome | 30 | 2028-05 |
| Donidalorsen NCT07298447 |
P3 | Recruiting | Hereditary Angioedema (HAE) | 20 | 2029-06 |
| Eplontersen NCT05071300 |
P3 | Active, not recruiting | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | 151 | 2029-08 (+61 mo) |
| Eplontersen NCT05667493 |
P3 | Enrolling by invitation | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | 1400 | 2029-08 (+4 mo) |
| Olezarsen NCT07727538 |
P3 | Recruiting | Familial Chylomicronemia Syndrome | 12 | 2030-08 |
| ION337 NCT07531745 |
P1/2 | Recruiting | Dravet Syndrome | 32 | 2030-12 |
| ION582 NCT05127226 |
P1/2 | Active, not recruiting | Angelman Syndrome | 71 | 2032-03 (+104 mo) |